ELDISINE vindesine sulfate 5mg powder for injection vial

Pajjiż: Awstralja

Lingwa: Ingliż

Sors: Department of Health (Therapeutic Goods Administration)

Ingredjent attiv:

vindesine sulfate, Quantity: 5 mg

Disponibbli minn:

Aspen Pharmacare Australia Pty Ltd

Għamla farmaċewtika:

Injection, powder for

Kompożizzjoni:

Excipient Ingredients: mannitol

Rotta amministrattiva:

Intravenous

Unitajiet fil-pakkett:

1 vial of powder 5mg

Tip ta 'preskrizzjoni:

(S4) Prescription Only Medicine

Indikazzjonijiet terapewtiċi:

This product accepted for registration/listing as 'currently supplied' at the time of commencement of the Act. Indications held in ARTG paper records. (Old code) ELDISINE is indicated in the palliative treatment of the following: Acute lymphocytic leukaemia of childhood resistant to other agents. Blastic crises of chronic myeloid leukaemia in adults. Non-small cell lung cancer. It should be noted that ELDISINE is usually given in combination with other oncolytic agents.

Sommarju tal-prodott:

Visual Identification: A white to off-white lyophilised plug; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store at 2 to 8 degrees Celsius

L-istatus ta 'awtorizzazzjoni:

Licence status A

Data ta 'l-awtorizzazzjoni:

1997-08-14